Inotiv, Inc.

NOTV

US45783Q1004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.05 ^USD	-5.59%		-8.37%	+10.35%

Mar. 19	Inotiv, Inc. Elects Michael J. Harrington as Class III Member of the Board	CI
Feb. 12	North American Morning Briefing : Stock Futures -2-	DJ

Inotiv, Inc. Terminates Employment of Joseph E. Flynn as Chief Commercial Officer

September 14, 2021 at 04:31 pm EDT

Inotiv, Inc. announced that on September 8, 2021, the Company terminated the employment of Joseph E. Flynn, its Chief Commercial Officer.

Latest news about Inotiv, Inc.

Inotiv, Inc. Elects Michael J. Harrington as Class III Member of the Board	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Feb. 12	DJ
Jefferies Upgrades Inotiv to Buy Rating From Hold, Adjusts Price Target to $11.50 From $3	Feb. 09	MT
Inotiv, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Transcript : Inotiv, Inc., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (NOTV) INOTIV Reports Q1 Revenue $135.5M, vs. Street Est of $132.9M	Feb. 07	MT
Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024	Feb. 07	CI
An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc..	Feb. 06	CI
Jefferies Adjusts Inotiv Price Target to $3 From $7.25, Maintains Hold Rating	Dec. 13	MT
Craig-Hallum Adjusts Price Target on Inotiv to $25 From $34, Maintains Buy Rating	Dec. 12	MT
Inotiv Q4 Loss Narrows, Revenue Falls; Issues Fiscal 2024 Guidance -- Shares Rise After Hours	Dec. 11	MT
Inotiv, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 11	CI
Earnings Flash (NOTV) INOTIV Reports Q4 Revenue $140.7M, vs. Street Est of $139.4M	Dec. 11	MT
Inotiv, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Dec. 11	CI
Inotiv, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Dec. 11	CI
Transcript : Inotiv, Inc., Q4 2023 Earnings Call, Dec 11, 2023	Dec. 11
Inotiv Guides For FY 2024 Revenue of $580-$590 Million, vs CIQ Analyst Consensus of $583 Million	Dec. 11	MT
Running the central bank gauntlet	Dec. 11	RE
North American Morning Briefing : Investors Await -2-	Dec. 11	DJ
Inotiv Unveils Partnership to Support Integration of North American Transportation Operations	Dec. 07	MT
Inotiv, Inc. Announces Changes to Its Board Composition	23-10-16	CI
Inotiv Closes Sale of Israeli Businesses to Harlan Holdings	23-08-30	MT
Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million.	23-08-28	CI
Health Care Limits Losses on Obesity-Drug Hopes -- Health Care Roundup	23-08-15	DJ
Transcript : Inotiv, Inc., Q3 2023 Earnings Call, Aug 10, 2023	23-08-10

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Inotiv, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.29 USD

Average target price

15.5 USD

Spread / Average Target

+261.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOTIV, INC.	+10.35%	111M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research

Inotiv, Inc.

Equities

NOTV

US45783Q1004

Biotechnology & Medical Research

Inotiv, Inc. Terminates Employment of Joseph E. Flynn as Chief Commercial Officer

Latest news about Inotiv, Inc.

Chart Inotiv, Inc.

Company Profile

Income Statement Evolution

Ratings for Inotiv, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research